The content on this site is intended for healthcare professionals only
Prof Jesus San Miguel presents data during press conference at the 18th EHA meeting in Stockholm.
Treatment for patients with multiple myeloma (MM) has improved over the last decade due to the introduction of new drugs such as lenalidomide and bortezomib.
However, after receiving multiple treatments, MM patients often become resistant (refractory) to these drugs and have an average survival of only 9 months.
MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, pomalidomide (POM) in combination with low-dose dexamethasone (POM LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage disease which have previously failed lenalidomide and bortezomib.
Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma
Understanding the remaining unmet needs in a post ASCT NDMM setting
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Multiple Myeloma: evolving paradigm - Panel Discussion
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
